Most founders have not.

That single gap, the distance between building a product and watching it function inside a real clinical environment, explains more health tech failures than any funding shortage, regulatory hurdle, or competitive threat combined.

I say this not as an observer, but as someone who has sat on both sides of the table. In 2017, I co-founded Caredose in New Delhi to solve medication non-adherence, a problem the WHO estimates costs the global healthcare system $637 billion annually. We built technology we were proud of. We raised capital. We partnered with institutes such as Max Hospitals, WHO, USAID, and the Gates Foundation. And then we walked into our first pharmacy chain and discovered that our elegant solution had one fundamental problem: it was designed around how we thought healthcare worked, not how it actually did.

That lesson took months to unlearn. It ultimately made Caredose better — we grew medicine adherence from under 50% to above 80% for our provider partners and achieved a successful exit. But the friction cost us time and resources we could not afford to waste. I have watched dozens of startups at Cedars-Sinai Technology Ventures, where I have now led over $20 million in institutional investments across 10+ companies. Our ambition is to ensure that they don’t make the exact same mistake, as it often leaves them without the runway to recover from it.

The Real Failure Mode: Technology-First, Patient-Last

The pattern is remarkably consistent. A founder identifies a genuine clinical problem. They build technically impressive software or hardware to address it. They secure pilots. The pilots produce promising data. And then— nothing. Adoption stalls, the hospital moves on. The startup runs out of money, wondering what went wrong.

What went wrong is almost always the same thing: the product was built to solve a technology problem, not a human behaviour problem.

Healthcare is not a rational system. It is an ecosystem of competing pressures, physicians managing 30-minute appointment windows, nurses following workflows designed decades ago, patients navigating fear and confusion alongside complex treatment regimens, and hospital administrators balancing budget cycles with clinical outcomes. A product that does not fit seamlessly into this reality, regardless of how good its algorithm is, will not be adopted.

At Caredose, we learned that getting a patient to take their medication on time was less about our IoT device and more about how the pharmacist explained it. The technology was 20% of the solution. The human trust layer was 80%.

Three Things Founders Must Do Differently

First, spend time in the workflow before you build for it. Not customer discovery calls, but actual observation. Sit in a hospital ward. Watch a pharmacy counter during peak hours. Understand where the friction lives before you decide where your solution fits.

Second, find your physician champion before you find your investor. In every health tech deal I have evaluated at Cedars-Sinai, the presence of an internal clinical advocate has been the single strongest predictor of adoption success. An investor can fund your technology. A physician champion can actually deploy it.

Third, treat patient behaviour as a design constraint, not a post-launch problem. Non-adherence, dropout, and low engagement— these are not user failures; they are design failures. Build the human trust layer into your product from day one, not as a feature update after your pilot.

What Must Change

India is producing exceptional health tech founders, technically rigorous, globally ambitious, and deeply motivated. What the ecosystem lacks is the infrastructure to help these founders stress-test their products against clinical reality before they go to market.

More hospital-founder partnerships. More operator-investors who have navigated both the startup and the clinical environment. More honest post-mortems from founders who built great technology that never reached a single patient.

The health tech problem worth solving in India is not a shortage of innovation. It is the last mile. And until we fix it, we will keep building brilliant solutions that fail quietly inside corridors the founders never walked.

Kinshuk Kocher is Director of Investment Operations & Special Projects at Cedars-Sinai Technology Ventures, Los Angeles. He is the co-founder of Caredose, a MedTech startup that created the simplest way of managing regular, chronic medication. He holds an MBA from the University of Oxford.

Mumbai (Maharashtra) [India] : Mumbai witnessed an emotional, glamorous, and star-studded evening at the grand Trailer & Music Launch of the much-awaited film “Hum Angrezon Ke Zamane Ke Jailor Hai”, regarded as the last film of legendary actor Asrani. The event was held at Aruba Bar & Experience and saw the presence of several renowned personalities from the entertainment industry.

The film stars an ensemble cast featuring Milind Gunaji, Zarina Wahab, Mushtaq Khan, and many others. Directed by Rakesh Sawant, the film is produced by Shweta Chauhan, Bhanwar Singh Pundir, and Rakesh Sawant.

One of the biggest highlights of the evening was the heartfelt tribute by Rakhi Sawant, who delivered a special, never-before-seen performance dedicated to Asrani Ji, celebrating his unforgettable contribution to Indian cinema. Her emotional act left the audience nostalgic and deeply moved.

The trailer received an overwhelming response from the media and attendees for its gripping narrative, powerful performances, and commercial entertainment value. The film revolves around a dark and intense murder mystery involving Thakur Vishwajeet Singh and Sawatei, whose family conflicts spiral into shocking crimes and suspenseful revelations. The investigation is led by Inspector Dev and Inspector Rana, taking audiences through a thrilling journey packed with drama, romance, action, music, and suspense.

Set against the scenic beauty of Uttarakhand, the film promises visually rich storytelling along with soulful music and emotional depth.

Director Rakesh Sawant said, “This film is extremely special and emotional for all of us because it carries the legacy and final performance of Asrani Ji. We wanted to create a complete entertainer while also giving audiences a memorable cinematic experience filled with suspense, emotion, and powerful performances.”

Producer Bhanwar Singh Pundir shared, “The response we received at the trailer launch has been overwhelming. It is a proud moment for our entire team to celebrate Asrani Ji’s incredible contribution to cinema through this film. Audiences will witness a perfect blend of thriller, entertainment, and emotion.”

Under the banner of Jaya Films and Gajanan Motion Movies, the film is produced by Shweta Chauhan, Bhanwar Singh Pundir, and Rakesh Sawant and directed by Rakesh Sawant.

The movie stars Asrani, Milind Gunaji, Zarina Wahab, Raksha Gupta, Muskan Verma, Vishnu Sharma, Abhinav Chauhan, and Mushtaq Khan.

“Hum Angrezon Ke Zamane Ke Jailor Hai” releases in cinemas on 12th June 2026.

Trailer link:  https://youtu.be/47x3HaalBAk?si=FY_SGLsxHi791uck

Indus Net Technologies, operating globally as INT. is that company. And after nearly three decades of building steadily, its relevance is becoming harder to ignore.

The Sectors That Cannot Afford to Get Technology Wrong

India's BFSI sector is undergoing its most consequential technology transition in a generation. The industry’s market cap is at ₹91 trillion ($1.1 trillion+), with India's fintech adoption rate standing at 87%, far above the global average of 67%. Digital payments alone may cross $10 trillion by 2026, driven by UPI, Aadhaar, and mobile penetration. Yet beneath these headline numbers, a structural gap persists. Indian BFSI entities currently allocate just 3 to 5% of revenue to technology, against global peers spending 8 to 10%. The platforms processing India's banking transactions are frequently running on architecture built for a different era.

Pharma faces a parallel reckoning. India's pharmaceutical sector, valued at nearly $65 billion, supplies approximately 20% of the world's generic medicines — and aspires to build a $130 billion market by 2030. The global pharma digital transformation market, valued at $18.4 billion in 2023, is expected to reach $45.2 billion by 2030, with 63% of pharma CEOs now citing digital transformation as a top priority for revenue growth. But HCP engagement platforms, pharmacovigilance workflows, and supply chain systems in most Indian pharma companies remain fragmented, legacy-dependent, and unready for the AI era.

These two sectors, high stakes, high complexity, and chronically under-digitised, are precisely where INT. has built its deepest delivery expertise.

What 28 Years of Enterprise Delivery Actually Looks Like

Founded in Kolkata in 1997 by Abhishek Rungta with a ₹50 investment and a conviction that Indian technology talent could serve global enterprises, INT. has grown into a 1,100+ professional enterprise operating across 45 countries from six global offices. It has delivered for IndusInd Bank, SBI General Insurance, DCB Bank, Bajaj Allianz Life Insurance, and Ageas Insurance (UK) in BFSI, and for Cipla in Life Sciences, among a 500+ client portfolio spanning Tesco, Honeywell, and Somax Inc. (USA).

The outcomes are not theoretical. A multilingual offline-ready portal built for SBI General Insurance delivered a 62% reduction in support requests and a 3x increase in claim tracker adoption among policyholders in Tier-2 and Tier-3 markets. A website redesign for DCB Bank produced a 70% improvement in mobile usability and a 40% reduction in bounce rate. For Bajaj Allianz Life Insurance, INT. automated the sales performance MIS process, eliminating manual reporting that had consumed dozens of hours of leadership time each week. For Ageas Insurance (UK), INT. built a mature product from scratch, now deployed at hundreds of sites across Europe.

These are not case studies. They are operating metrics inside India's most scrutinised financial institutions.

The Full-Stack Difference

What distinguishes INT. from the niche vendors that crowd India's enterprise technology market is the breadth of capability delivered under a single partnership. Leading pharma companies are now embedding AI, automation, and digital twins into every layer of the enterprise, connecting R&D, manufacturing, commercial, and supply chain into a single responsive network. INT.'s Life Sciences practice, anchored by its Cipla engagement, is precisely positioned to deliver that integration without the client managing multiple vendor relationships.

Recognised five consecutive times as a Great Place to Work, ranked in the Deloitte Technology Fast 50 and Fast 500 Asia Pacific, and now a pre-IPO company with DRHP filed in 2024, INT. is entering a new chapter, with the same foundational conviction Abhishek Rungta had in 1997: that technology is only worth building if it makes a measurable difference to the business it serves.

For India's banks, insurers, and pharma companies, that difference has been quietly compounding for nearly three decades.

INT. (Indus Net Technologies) is a full-stack digital transformation company headquartered in Kolkata, India. With 1,100+ professionals, 500+ enterprise clients across 45 countries. INT. delivers AI, Cloud, Cybersecurity, Digital Engineering, and Customer Experience solutions for BFSI, Life Sciences, and Retail enterprises. Learn more at intglobal.com.